Ultragenyx Pharmaceutical (NASDAQ:RARE) Issues Quarterly Earnings Results, Misses Estimates By $0.31 EPS

Ultragenyx Pharmaceutical (NASDAQ:RARE) issued its earnings results on Thursday. The biopharmaceutical company reported ($2.03) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.72) by ($0.31), Briefing.com reports. The company had revenue of $108.83 million during the quarter, compared to analyst estimates of $116.03 million. Ultragenyx Pharmaceutical had a negative net margin of 139.70% and a negative return on equity of 369.54%. The business’s quarterly revenue was up 8.3% on a year-over-year basis. During the same quarter in the prior year, the business earned ($2.33) EPS.

Ultragenyx Pharmaceutical Stock Down 1.0 %

Ultragenyx Pharmaceutical stock traded down $0.45 during trading hours on Friday, reaching $42.75. 1,143,007 shares of the company’s stock were exchanged, compared to its average volume of 767,975. The firm has a market capitalization of $3.55 billion, a PE ratio of -5.13 and a beta of 0.68. The firm’s 50 day simple moving average is $47.25 and its 200 day simple moving average is $44.08. Ultragenyx Pharmaceutical has a twelve month low of $31.52 and a twelve month high of $54.98.

Insider Transactions at Ultragenyx Pharmaceutical

In related news, EVP Karah Herdman Parschauer sold 3,756 shares of the stock in a transaction on Friday, March 1st. The shares were sold at an average price of $53.76, for a total transaction of $201,922.56. Following the transaction, the executive vice president now directly owns 67,340 shares of the company’s stock, valued at $3,620,198.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Ultragenyx Pharmaceutical news, EVP Karah Herdman Parschauer sold 3,756 shares of the stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $53.76, for a total value of $201,922.56. Following the transaction, the executive vice president now owns 67,340 shares in the company, valued at $3,620,198.40. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider John Richard Pinion sold 4,173 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $53.76, for a total value of $224,340.48. Following the sale, the insider now owns 89,268 shares of the company’s stock, valued at approximately $4,799,047.68. The disclosure for this sale can be found here. Insiders sold a total of 32,116 shares of company stock valued at $1,645,983 in the last quarter. 6.80% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on RARE shares. TD Cowen boosted their price objective on Ultragenyx Pharmaceutical from $59.00 to $61.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $107.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Friday. Robert W. Baird lifted their target price on shares of Ultragenyx Pharmaceutical from $57.00 to $68.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 30th. JPMorgan Chase & Co. upped their price target on shares of Ultragenyx Pharmaceutical from $88.00 to $92.00 and gave the company an “overweight” rating in a research report on Monday, March 18th. Finally, Wedbush cut their price target on shares of Ultragenyx Pharmaceutical from $48.00 to $47.00 and set a “neutral” rating on the stock in a report on Friday. Two research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $88.00.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.